U.S. Markets open in 7 hrs 25 mins

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results

Conference Call and Webcast Scheduled for Monday, April 29

SAN DIEGO, April 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 29, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

(PRNewsfoto/Neurocrine Biosciences, Inc.)

Participants can access the live conference call by dialing 877-876-9173 (US) or 785-424-1667 (International) using the conference ID: NBIX. The webcast can also be accessed on Neurocrine's website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed and markets INGREZZA® (valbenazine) capsules, the first FDA-approved treatment for adults with tardive dyskinesia, an involuntary movement disorder. Neurocrine also discovered and led the Phase II clinical development of ORILISSA® (elagolix), the first FDA-approved oral medication for the management of endometriosis with associated moderate to severe pain in over a decade, which is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for women's health. Neurocrine's clinical development programs include opicapone, an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for Parkinson's disease patients, elagolix for uterine fibroids (with AbbVie), valbenazine for the treatment of Tourette syndrome, NBI-74788 for the treatment of congenital adrenal hyperplasia (CAH), and early-stage gene therapies for neurological disorders including Parkinson's disease and Friedreich's ataxia, acquired through a collaboration with Voyager Therapeutics. For more information and the latest updates from Neurocrine Biosciences, please visit www.neurocrine.com.

 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2019-financial-results-300826326.html